公开(公告)号：US20230348990A1

公开(公告)日：2023-11-02

申请号：US18016942

申请日：2021-07-20

Applicant: The Institute of Cancer Research: Royal Cancer Hospital

Inventor： Melissa Tan ,  Robert Huddart ,  Anguraj Sadanandam ,  Gift Nyamundanda

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/158 ,  C12Q2600/118 ,  C12Q2600/106

Abstract: The present invention provides a method for predicting the treatment response of a human bladder cancer patient, the method comprising: a) measuring the gene expression of at least 9, at least 10, at least 15, at least 20 or at least 30 of the genes from Group 1 in Table 10 and at least 1, at least 2, at least 3 or at least 5 of the genes from Groups 2-4 in Table 10 in a sample obtained from the bladder tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Related methods and systems are also described. The invention finds particular use in predicting whether a bladder cancer patient is likely to be sensitive to (chemo)radiation therapy.

公开(公告)号：US11788148B2

公开(公告)日：2023-10-17

申请号：US16755085

申请日：2018-10-12

Applicant: The Institute of Cancer Research: Royal Cancer Hospital ,  The Royal Marsden NHS Foundation Trust ,  National University of Singapore

Inventor： Elizabeth Smyth ,  Anguraj Sadanandam ,  Gift Nyamundanda ,  David Cunningham ,  Boon Ooi Patrick Tan

IPC: C12Q1/6886

CPC classification number: C12Q1/6886 ,  C12Q2600/106 ,  C12Q2600/118 ,  C12Q2600/158 ,  G01N2800/52 ,  G01N2800/7028

Abstract: The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

公开(公告)号：US20200239968A1

公开(公告)日：2020-07-30

申请号：US16755085

申请日：2018-10-12

Applicant: The Institute of Cancer Research: Royal Cancer Hospital ,  The Royal Marsden NHS Foundation Trust ,  National University of Singapore

Inventor： Elizabeth Smyth ,  Anguraj Sadanandam ,  Gift Nyamundanda ,  David Cunningham ,  Boon Ooi Patrick Tan

IPC: C12Q1/6886

Abstract: The present invention provides a method for predicting the treatment response of a human gastroesophageal cancer patient, the method comprising: a) measuring the gene expression of at least 3 of the following genes: CDH1, CDK6, COX2, ELOVL5, GATA4, EGFR, TBCEL, FGF7, CDH17, FNBP1, PIP5K1B, TWIST, CD44, MET, CEACAM1, TOX3, GLIPR2, GSTP1, RON, TMEM136, MYB, BRCA2, FGF1, POU5F1, EPR, DPYD, ABL2 and SH3RF1 in a sample obtained from the gastroesophageal tumour of the patient to obtain a sample gene expression profile of at least said genes; and b) making a prediction of the treatment response and/or prognosis of the patient based on the sample gene expression profile. Also provided are related computer-implemented methods and methods of treatment of gastroesophageal cancer.

公开(公告)号：US20210102260A1

公开(公告)日：2021-04-08

申请号：US16970178

申请日：2019-02-15

Applicant: The Institute of Cancer Research: Royal Cancer Hospital ,  The Royal Marsden NHS Foundation Trust ,  ARC-NET Centre for Applied Research on Cancer Universita Degli Studi Di Verona

Inventor： Anguraj Sadanandam ,  Gift Nyamundanda ,  Kate Young ,  Aldo Scarpa ,  Chanthirika Ragulan

IPC: C12Q1/6886 ,  G16B25/10

Abstract: The present invention relates to methods for predicting prognosis and overall survival among tumour/cancer patients, and methods for classifying and stratifying these patients, particularly patients having pancreatic neuroendocrine tumors (PanNETs). The invention also relates to therapeutic methods for treating classified patients. Measuring gene expression levels of at least some of a selected group 198 genes is shown to be useful in the stratification of patients into groups with prognostic significance, and making a prediction of prognosis.